TABLE 13: Treatment - teletherapy

% of Cases treated with Teletherapy
Country average (population) Country average (country) England Scotland Wales1 Northern Ireland Republic of Ireland
All invasive xnmsc 19.8% 20.5% 19.8% NA 19.5% 22.3%
All xnmsc 0-24 12.5% 12.9% 12.5% NA 10.6% 15.5%
All xnmsc 25-59 22.7% 23.9% 22.6% NA 24.6% 24.5%
All xnmsc 60-79 21.9% 21.5% 22.0% NA 21.1% 21.4%
All xnmsc 80+ 11.8% 11.5% 11.8% NA 11.1% 11.6%
Haematology 9.0% 9.3% 9.1% NA 7.4% 11.6%
Head and Neck 60.1% 59.7% 60.2% NA 59.4% 59.6%
Lower GI 12.9% 13.0% 12.9% NA 11.6% 14.4%
Upper GI 18.1% 15.8% 18.3% NA 21.0% 8.2%
HPB 2.1% 3.1% 1.9% NA 2.7% 4.7%
Trachea, Bronchus & Lung 26.4% 26.4% 26.3% NA 28.2% 24.6%
Melanoma of skin 0.8% 0.7% 0.8% NA 0.6% 0.9%
Breast 37.6% 37.0% 37.6% NA 38.6% 34.8%
Prostate 40.9% 47.3% 40.3% NA 42.4% 59.1%
Cervix 9.2% 13.1% 8.7% NA 13.7% 16.9%
Other Female Genitals 18.6% 16.5% 19.0% NA 11.9% 18.5%
Kidney 5.3% 7.1% 5.1% NA 7.1% 9.0%
Bladder 17.6% 16.9% 17.7% NA 17.0% 16.0%
Brain and CNS 48.0% 44.7% 48.5% NA 42.5% 43.0%
Thyroid & other endocrine glands 8.8% 15.1% 8.0% NA 16.9% 20.4%
CUP 11.5% 10.2% 11.6% NA 11.8% 7.1%
Other invasive cancer 11.6% 11.1% 11.7% NA 10.0% 11.5%
Breast in situ 32.3% 34.3% 32.1% NA 29.9% 41.1%
Cervix in situ 0.0% 0.1% 0.0% NA 0.2% 0.0%
Other tumours 1.1% 1.5% 0.9% NA 1.3% 2.4%
Non-Melanoma Skin Cancer 1.8% 1.3% 1.9% NA 1.1% 0.8%

1 Data for Wales is on the preceding year.